Angiotensinogen, Angiotensin-Converting Enzyme, and Chymase Gene Polymorphisms as Biomarkers for Basal Cell Carcinoma Susceptibility.
A1903G
ACE
AGT
Angiotensin II
Basal cell carcinoma
CMA1
Cancer
Genetic association
I/D
M235T
Journal
Advances in experimental medicine and biology
ISSN: 0065-2598
Titre abrégé: Adv Exp Med Biol
Pays: United States
ID NLM: 0121103
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
23
10
2023
pubmed:
1
8
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
The intake of angiotensin-converting enzyme (ACE) inhibitors and specific antagonists of angiotensin II receptors, widely used as antihypertensive drugs, significantly reduces the risk of developing basal cell carcinoma (BCC), highlighting the possible tumorigenic role of angiotensin II (AngII). We present here the investigated genetic association between the development of BCC and functional DNA polymorphisms M235T, I/D, and A1903G in the genes of angiotensinogen (AGT), angiotensin-converting enzyme (ACE), and chymase (CMA1), which mediate AngII production levels. DNA samples of 203 unrelated Greeks were studied, including 100 patients with BCC and 103 matched healthy controls. The MT genotype of the AGT-M235T polymorphism was significantly more prevalent in the patient group (78.0%) versus the healthy control group (28.3%; p < 0.001). The DD genotype of the ACE-I/D polymorphism was also increased in BCC patients (72.8%) compared to controls (46.2%; p = 0.001). The heterozygous AG genotype of CMA1-A1903G was significantly more frequent in the BCC group (86%) than in the healthy controls (50.5%; p < 0.001). The MT, DD, and AG genotypes of the AGT- M235T, ACE-I/D, and CMA1-A1903G polymorphisms, respectively, were significantly increased in frequency within the group of cancer patients compared to the healthy controls. All three genotypes correspond to increased enzyme levels or activity and result in increased levels of AngII; therefore, they may be potentially utilized as reliable biomarkers associated with an individual's increased risk for BCC development.
Identifiants
pubmed: 37525041
doi: 10.1007/978-3-031-31978-5_14
doi:
Substances chimiques
Angiotensinogen
11002-13-4
Chymases
EC 3.4.21.39
Angiotensin II
11128-99-7
Peptidyl-Dipeptidase A
EC 3.4.15.1
Serine Proteases
EC 3.4.-
Biomarkers
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-180Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Montagna E, Lopes OS (2017) Molecular basis of basal cell carcinoma. An Bras Dermatol 92(4), 517–520
doi: 10.1590/abd1806-4841.20176544
pubmed: 28954101
pmcid: 5595599
McDaniel B, Badri T, Steele RB (2022) Basal Cell Carcinoma. StatPearls
Gupta N, Ruiz ES (2022) Current Perspectives in the Treatment of Locally Advanced Basal Cell Carcinoma. Drug Des Devel Ther 16:183–190
doi: 10.2147/DDDT.S325852
pubmed: 35058688
pmcid: 8765439
Hollestein LM, De Vries E, Aarts MJ, Schroten C, Nijsten TEC (2014) Burden of disease caused by keratinocyte cancer has increased in The Netherlands since 1989. J Am Acad Dermatol 71(5):896–903
doi: 10.1016/j.jaad.2014.07.003
pubmed: 25190484
Pellegrini C, Maturo MG, Di Nardo L, Ciciarelli V, Gutiérrez García-Rodrigo C, Fargnoli MC (2017) Understanding the Molecular Genetics of Basal Cell Carcinoma. Int J Mol Sci 18(11):2485
doi: 10.3390/ijms18112485
pubmed: 29165358
pmcid: 5713451
Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA (2008) Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100(17):1223–1232
doi: 10.1093/jnci/djn262
pubmed: 18728281
Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, Bertoni E, Salvadori M (2010) Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol 73(6):439–445
doi: 10.5414/CNP73439
pubmed: 20497756
George AJ, Thomas WG, Hannan RD (2010) The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer 10(11):745–759
doi: 10.1038/nrc2945
pubmed: 20966920
Gintoni I, Adamopoulou M, Yapijakis C (2021) The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications. In Vivo 35(1):95–103
doi: 10.21873/invivo.12236
pubmed: 33402454
pmcid: 7880778
Varney VA, Nicholas A, Warner A, Sumar N (2019) IgE-mediated systemic anaphylaxis and its association with gene polymorphisms of ACE, angiotensinogen and chymase. J Asthma Allergy 12: 343–361
doi: 10.2147/JAA.S213016
pubmed: 31632094
pmcid: 6790349
Yapijakis C, Koronellos N, Spyridonidou S, Vylliotis A, Avgoustidis D, Goutas N, Vlachodimitropoulos D, Vairaktaris E (2013) Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with decreased risk for basal cell carcinoma. Arch Dermatol Res 305(4):333–339.
doi: 10.1007/s00403-012-1312-7
pubmed: 23299466
Papaggelopoulos J, Angelopoulou A, Avgoustidis D, Koronellos N, Derka S, Vassiliou S, Yapijakis C (2019) Association of Polymorphisms in the Genes of Angiotensinogen and Angiotensin Receptors With Risk for Basal Cell Carcinoma. Anticancer Res 39(10):5525–5530
doi: 10.21873/anticanres.13745
pubmed: 31570446
Gintoni I, Vassiliou S, Avgoustidis D, Adamopoulou M, Zavras N, Papakosta V, Vlachakis D, Yapijakis C (2021) Lack of Association Between the ACE2G8790A Gene Variation and Risk for Basal Cell Carcinoma. Anticancer Res 41(8):4021–4026
doi: 10.21873/anticanres.15201
pubmed: 34281868
Charalampidou S, Gintoni I, Avgoustidis D, Papakosta V, Vlachakis D, Vassiliou S, Yapijakis C (2022) Association between a high gene expression variant of chymase and increased risk for basal cell carcinoma. Anticancer Res (in press)
Xi B, Zeng T, Liu L, Liang Y, Liu W, Hu Y, Li J (2011) Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 130(2):561–568
doi: 10.1007/s10549-011-1602-3
pubmed: 21638051
Gintoni I, Adamopoulou M, Yapijakis C (2022) The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19. In Vivo 36(1):13–29
doi: 10.21873/invivo.12672
pubmed: 34972696
pmcid: 8765175